15 June 2026
15 June 2026
The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.
The MHRA’s approval of a lower dose of EURneffy means more children will have a needle-free option to treat anaphylaxis.
Derisking assets to attract capital and rethinking funding models should be key priorities for Europe to retain its research pipeline.
If the research is successful, Simcere may in-license the molecule and obtain all global rights to the product.
While rare disease research has advanced significantly, related expertise and data are scattered across too many disconnected places.
The approvals are based on data from the pivotal Phase III LITESPARK-022 trial, which enrolled 1,841 patients.
According to GlobalData POLI, the average time to reimburse in Canada for all branded drugs has steadily increased.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
